Publications by authors named "K V Gleixner"
Background: Platelets are pivotal in maintaining vascular integrity, hemostasis, and immune modulation, with newly generated, immature platelets being the most responsive in fulfilling these tasks. Therefore, the immature platelet fraction provides insights into thrombopoiesis dynamics and clinical prognostication. However, it is currently unclear how immature platelet functions change in settings of acute thrombocytopenia.
View Article and Find Full Text PDFArticle Synopsis
- * Antifungal prophylaxis has reduced IFD occurrences but has also changed the types of fungal pathogens seen, necessitating broader screening methods for early diagnosis and treatment.
- * A study analyzed blood samples from high-risk patients using advanced PCR techniques, revealing that many detectable fungi were typically non-pathogenic, highlighting the need for repeated testing and accurate identification to guide effective treatment.
Immune thrombotic thrombocytopenic purpura (iTTP) is a rare, life-threatening autoimmune disorder caused by a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13 (ADAMTS13) deficiency. Caplacizumab, an anti-von Willebrand factor nanobody, is approved for iTTP treatment, reducing the need for therapeutic plasma exchange (TPE) and improving platelet count recovery and survival. We conducted a retrospective study on 42 acute iTTP cases in Austria and Germany, treated with a modified regimen aimed at avoiding TPE if platelet count increased after the first caplacizumab dose.
View Article and Find Full Text PDFArticle Synopsis
- Acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) are serious blood cancers that involve the rapid increase of abnormal white blood cells, and recent research has highlighted BRD4 and MYC as potential targets for new drug therapies.
- In experiments comparing various BRD4-targeting drugs, including the BET inhibitor JQ1 and BRD4 degraders dBET1 and dBET6, all three were effective at reducing the growth of AML and ALL cells, including resistant leukemic stem cells.
- Notably, dBET6 outperformed the others by overcoming drug resistance, showing especially promising results when paired with other medications, and it also inhibited the expression of the resistance-related PD-L1 antigen in
Certain laboratory abnormalities correlate with subvariants of systemic mastocytosis (SM) and are often prognostically relevant. To assess the diagnostic and prognostic value of individual serum chemistry parameters in SM, 2607 patients enrolled within the European Competence Network on Mastocytosis and 575 patients enrolled within the German Registry on Eosinophils and Mast Cells were analyzed. For screening and diagnosis of SM, tryptase was identified as the most specific serum parameter.
View Article and Find Full Text PDF